Skip to main content
Top
Published in: Medical Oncology 2/2012

01-06-2012 | Original Paper

Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells

Authors: Xu-yuan Li, Ying-cheng Lin, Wan-lan Huang, Chao-qun Hong, Jiong-yu Chen, Yan-jie You, Wei-bing Li

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

To demonstrate the effect of zoledronic acid in proliferation, invasion, and migration of human nasopharyngeal carcinoma cell HNE-1 and explore the potential role of VEGF, MMP-2, and MMP-9 proteins in vitro. Human nasopharyngeal carcinoma cell HNE-1 was exposed to various concentrations (0–40 μmol/l) of zoledronic acid. Zoledronic acid inhibited proliferation of HNE-1 cells though not in a dose-dependent manner. Zoledronic acid had exerted a dose-dependent effect on the migration and invasion of HNE-1 cells. Both expressions of mRNA and protein of MMP2, MMP9, and VEGF were reduced, respectively, detected by RT-PCR and Western blot assays. These data suggested that zoledronic acid not only inhibited growth but also invasion and migration of HNE-1 cells in vitro. The anti-cancer action of zoledronic acid was partially associated with the suppression of VEGF expression and secretion and downregulating the expression of MMP2 and MMP9.
Literature
1.
go back to reference Mcderrmott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci. 2001;26:82–92.CrossRef Mcderrmott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci. 2001;26:82–92.CrossRef
2.
go back to reference Arango BA, Castrellon AB, Perez CA, Raez LE, Santos ES. Nasopharyngeal carcinoma: alternative treatment options after disease progression. Expert Rev Anticancer Ther. 2010;10:377–86.PubMedCrossRef Arango BA, Castrellon AB, Perez CA, Raez LE, Santos ES. Nasopharyngeal carcinoma: alternative treatment options after disease progression. Expert Rev Anticancer Ther. 2010;10:377–86.PubMedCrossRef
3.
go back to reference Caponigro F, Longo F, Ionna F, Perri F. Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs. 2010;21:471–7.PubMedCrossRef Caponigro F, Longo F, Ionna F, Perri F. Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs. 2010;21:471–7.PubMedCrossRef
4.
5.
go back to reference Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T. Zoledronic acid—a multiplicity of anti-cancer action. Curr Med Chem. 2007;14:2126–35.PubMedCrossRef Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T. Zoledronic acid—a multiplicity of anti-cancer action. Curr Med Chem. 2007;14:2126–35.PubMedCrossRef
6.
go back to reference Clézardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 2005;65:4971–4.PubMedCrossRef Clézardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 2005;65:4971–4.PubMedCrossRef
7.
go back to reference Winter MC, Holen I, Coleman RE. Exploring the anti-tumor activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008;34:453–75.PubMedCrossRef Winter MC, Holen I, Coleman RE. Exploring the anti-tumor activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008;34:453–75.PubMedCrossRef
8.
go back to reference Gnant M, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679–91.PubMedCrossRef Gnant M, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679–91.PubMedCrossRef
9.
go back to reference Rack B, et al. Effect of zoledronate on persisting isolated tumor cells in patients with early breast cancer. Anticancer Res. 2010;30:1807–13.PubMed Rack B, et al. Effect of zoledronate on persisting isolated tumor cells in patients with early breast cancer. Anticancer Res. 2010;30:1807–13.PubMed
10.
go back to reference Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer. 2003;88:1631–40.PubMedCrossRef Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer. 2003;88:1631–40.PubMedCrossRef
11.
go back to reference Hasmim M, Bieler G, Rüegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost. 2007;5:166–73.PubMedCrossRef Hasmim M, Bieler G, Rüegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost. 2007;5:166–73.PubMedCrossRef
12.
go back to reference Goffinet M, et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer. 2006;6:60.PubMedCrossRef Goffinet M, et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer. 2006;6:60.PubMedCrossRef
13.
go back to reference Boissier S, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60:2949–54.PubMed Boissier S, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60:2949–54.PubMed
14.
go back to reference Ferretti G, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology. 2005;69:35–43.PubMedCrossRef Ferretti G, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology. 2005;69:35–43.PubMedCrossRef
15.
go back to reference Santini D, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13:4482–6.PubMedCrossRef Santini D, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13:4482–6.PubMedCrossRef
16.
go back to reference Facchini G, et al. Metronomic administration of zoledronic acid, taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther. 2010;10:6. Facchini G, et al. Metronomic administration of zoledronic acid, taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther. 2010;10:6.
17.
go back to reference Aft R, et al. Effect of zoledronic acid on disseminated tumor cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010;11:421–8.PubMedCrossRef Aft R, et al. Effect of zoledronic acid on disseminated tumor cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010;11:421–8.PubMedCrossRef
18.
go back to reference Ottewell PD, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008;14:4658–66.PubMedCrossRef Ottewell PD, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008;14:4658–66.PubMedCrossRef
19.
go back to reference Fabbri F, et al. Zoledronic acid increases docetaxel cytotoxicity through pMEK, Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med. 2008;6:43.PubMedCrossRef Fabbri F, et al. Zoledronic acid increases docetaxel cytotoxicity through pMEK, Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med. 2008;6:43.PubMedCrossRef
20.
go back to reference Giraudo E, Hanahan D. Zoledronia acid inhibit angiogenesis and impairs tumorigenesis in a mouse model of cervical carcinogenesis. Haematol Rep. 2006;2:39–41. Giraudo E, Hanahan D. Zoledronia acid inhibit angiogenesis and impairs tumorigenesis in a mouse model of cervical carcinogenesis. Haematol Rep. 2006;2:39–41.
21.
go back to reference Bäckman U, Svensson A, Christofferson RH, Azarbayjani F. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res. 2008;28:1551–7.PubMed Bäckman U, Svensson A, Christofferson RH, Azarbayjani F. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res. 2008;28:1551–7.PubMed
22.
go back to reference Soltau J, et al. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res. 2008;28:933–41.PubMed Soltau J, et al. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res. 2008;28:933–41.PubMed
23.
go back to reference Li YY, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 2008;59:180–91.PubMedCrossRef Li YY, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 2008;59:180–91.PubMedCrossRef
24.
go back to reference Karabulut B, et al. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int. 2009;33:239–46.PubMedCrossRef Karabulut B, et al. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int. 2009;33:239–46.PubMedCrossRef
25.
go back to reference Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.PubMedCrossRef Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.PubMedCrossRef
26.
go back to reference Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life. 2001;52:61–6.PubMedCrossRef Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life. 2001;52:61–6.PubMedCrossRef
27.
go back to reference Evans KD, Oberbauer AM. Alendronate inhibits VEGF expression in growth plate chondrocytes by acting on the mevalonate pathway. Open Orthop J. 2009;3:83–8.PubMedCrossRef Evans KD, Oberbauer AM. Alendronate inhibits VEGF expression in growth plate chondrocytes by acting on the mevalonate pathway. Open Orthop J. 2009;3:83–8.PubMedCrossRef
28.
go back to reference Santini D, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13:4482–6.PubMedCrossRef Santini D, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13:4482–6.PubMedCrossRef
29.
go back to reference Montague R, et al. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of zoledronic acid in prostate cancer. Eur Urol. 2004;46:389–402.PubMedCrossRef Montague R, et al. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of zoledronic acid in prostate cancer. Eur Urol. 2004;46:389–402.PubMedCrossRef
30.
go back to reference Li YY, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 2008;59:180–91.PubMedCrossRef Li YY, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 2008;59:180–91.PubMedCrossRef
Metadata
Title
Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells
Authors
Xu-yuan Li
Ying-cheng Lin
Wan-lan Huang
Chao-qun Hong
Jiong-yu Chen
Yan-jie You
Wei-bing Li
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9904-1

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.